Amar­in's Vas­cepa reigns supreme in fish oil bat­tle, as As­traZeneca's ri­val fiz­zles

As­traZeneca’s com­pet­i­tive threat to Amarin’s mighty Vas­cepa in pa­tients with car­dio­vas­cu­lar risk has wilt­ed.

On Mon­day, the British drug­mak­er said it was aban­don­ing a large car­dio­vas­cu­lar (CV) out­comes tri­al test­ing its fish oil pill Epano­va af­ter an in­de­pen­dent da­ta mon­i­tor­ing com­mit­tee pre­dict­ed the ther­a­py had a low like­li­hood of demon­strat­ing a ben­e­fit to pa­tients with mixed dys­lip­i­daemia who car­ry a high risk of CV dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER